As Eli Lilly's Mounjaro prescriptions skyrocket, analyst predicts $50B in yearly tirzepatide sales
No matter how you look at it, the obesity drug market is shaping up to be vast. And the spotlight right now is on Eli Lilly’s tirzepatide, which was approved last year as Mounjaro for type 2 diabetes and is already under rolling submission as an obesity treatment.
The current flurry of interest comes in advance of new data expected this month from its second SURMOUNT study at the same time that Mounjaro prescriptions are skyrocketing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.